Form 6-K OKYO Pharma Ltd For: May 19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

May 2022

 

 

Commission File Number: 001-41386

 

 

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

 

 

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On May 19, 2022, OKYO Pharma LTD (the “Company”) issued a news service announcement in the United States Closing of Offering.

 

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	OKYO Pharma LTD
Date: May 19, 2022	By:	/s/ Gary Jacob
	Name:	Gary Jacob
	Title:	Chief Executive Officer

 

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		News Service Announcement, dated May 19, 2022

 

 

Exhibit 99.1

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSE OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF UNITED KINGDOM (“UK”) DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (“UK MAR”). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

OKYO Pharma Limited
(“OKYO” or the “Company”)

 

Closing of Offering

 

London and New York, 19 May 2022 – OKYO Pharma Limited (LSE: OKYO; Nasdaq: OKYO) (“OKYO” or the “Company”), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce the closing of its initial public offering of 625,000 American Depositary Shares (“ADSs”) representing 40,625,000 of the Company’s ordinary shares of no par value each (“Ordinary Shares”) (the “Offering”) at a price of $4.00 per ADS, for aggregate proceeds of approximately $2,500,000, before deducting underwriting discounts and commissions. Each ADS offered in the Offering represents 65 Ordinary Shares.

 

OKYO’s ADSs are trading on the Nasdaq Capital Market under the ticker symbol “OKYO”.

 

ThinkEquity LLC acted as sole bookrunning manager on the Offering. A registration statement, including a prospectus, relating to these securities has been filed by OKYO and was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on 16 May 2022. Copies of the registration statement relating to and describing the terms of the Offering may be obtained from ThinkEquity, 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at [email protected]. Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the SEC’s website at http://www.sec.gov.

 

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

- Ends -

 

For the purposes of UK MAR, the person who arranged the release of this information is Gary S. Jacob, Chief Executive Officer.

 

For further information, please contact:

 

OKYO Pharma Limited
Gary S. Jacob, Chief Executive Officer	+44 (0)20 7495 2379
Gabriele Cerrone, Non-Executive Chairman
ThinkEquity, a division of Fordham Financial Management, Inc.	(877) 436-3673
Ramnarain Jaigobind
Priyanka Mahajan
RedChip Companies Inc. (Investor Relations)	+1 407-491-4498
Dave Gentry

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ClimeCo Launches 4Nature, a Set of High-Profile, Large Scale Decarbonization, Biodiversity Restoration and Social Impact Projects in Unique Global Locations
• Asia Pacific continues to lead the world in the adoption of local payment methods - new research from Boku reveals
• Tquila announces launch and first close of $60 million Tquila Paloma Fund, marking milestone in tech venture investment